State Street Corp Boosts Holdings in Becton, Dickinson and Company $BDX

Key Points

• State Street increased its Becton, Dickinson and Company stake by 8.5% to 15.0 million shares, worth approximately $2.27 billion. Institutional investors and hedge funds collectively own 86.97% of BDX.
• BD reported quarterly earnings of $3.23 per share, exceeding estimates, while revenue rose 5.4% year over year to $4.98 billion. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
• Analysts remain mixed, with an overall “Hold” rating and an average price target of $187.67; BDX recently traded at $183.30. The company also declared a quarterly dividend of $1.05 per share, implying a 2.3% annual yield.

State Street Corp increased its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 8.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,000,064 shares of the medical instruments supplier's stock after buying an additional 1,177,256 shares during the quarter. State Street Corp owned about 5.44% of Becton, Dickinson and Company worth $2,269,960,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BDX. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $3,721,533,000. First Eagle Investment Management LLC grew its stake in Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares in the last quarter. Geode Capital Management LLC increased its holdings in Becton, Dickinson and Company by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier's stock worth $1,331,165,000 after purchasing an additional 53,884 shares during the period. Auto Owners Insurance Co raised its position in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after purchasing an additional 40,528,680 shares in the last quarter. Finally, Norges Bank acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $734,321,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on BDX shares. The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 27th. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Bank of America raised their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Monday, August 31st. Jefferies Financial Group reiterated a "buy" rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $187.67.

Becton, Dickinson and Company Stock Up 1.4%

Shares of NYSE:BDX opened at $183.30 on Wednesday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock has a market cap of $50.51 billion, a P/E ratio of 55.21, a P/E/G ratio of 12.74 and a beta of 0.21. The firm has a fifty day moving average price of $176.65 and a 200 day moving average price of $160.75.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,905 shares of company stock valued at $1,263,354. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.